CNS Network selects ALPHADAS®, Logos Technologies Early Phase EDC System

    http://www.logostechnologies.com/files/news/CNSNetwork.html

---------------------------------------------------------------------------------------------------------------

Collaborative Neuroscience Network in California Opens Dedicated Phase I Facility in May 2010

 

FutureSearch Trials and Collaborative Neuroscience have completed phase I QTc studies in subjects with schizophrenia.

Protocol titles include:

An Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of XXX on the Steady-State Pharmacokinetics of XXX in Clinically Stable Subjects with Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder

An Open-label, Parallel-arm, Two-period, Single-dose Pilot Study to Assess the Pharmacokinetics and the Effect of Food on the Pharmacokinetics of Five Once Weekly Oral Formulations of XXX in Adult Subjects with Schizophrenia

A Multicenter, Double-Blind, Randomized, Parallel Group, Active-Controlled Tolerability and Safety Study of XXX in Clinically Stable Schizophrenic Outpatients

A Placebo- And Positive-Controlled, Randomized Study, Evaluating Qt And Qtc Intervals Following Administration Of An Immediate-Release Atypical Antipsychotic In Subjects With Schizophrenia Or Schizoaffective Disorder

 

A Placebo- And Positive-Controlled, Randomized Study, Evaluating Qt And Qtc Intervals Following Administration Of Immediate-Release An Atypical Antipsychotic In Subjects With Schizophrenia Or Schizoaffective Disorder

 

Please contact Bobbie to learn more about these capabilities and Phase I expansion plans.